Oligometastatic disease does not preclude effective pelvic exenteration

Long-term survival is achievable in selected patients with locally recurrent rectal cancer, even when presenting with synchronous or previously treated metastatic disease. In a study of 300 patients undergoing pelvic exenteration, five-year overall survival rates reached 41%, despite a notable proportion having a history of metastases. Although survival tended to be lower in those with metastatic disease (25% vs 45%), these findings suggest that oligometastatic disease should not automatically disqualify patients from radical surgical interventions.